Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 5 of 242 for:    Open Studies | "Lower Urinary Tract Symptoms"

Bladder Wall Blood Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarincs for Female Overactive Bladder Syndrome.

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Far Eastern Memorial Hospital
National Science Council, Taiwan
Information provided by (Responsible Party):
Sheng-Mou Hsiao, Far Eastern Memorial Hospital Identifier:
First received: January 23, 2011
Last updated: September 4, 2016
Last verified: September 2016
Overactive bladder syndrome (OAB) affects around 17 % of female population. However, the etiology of OAB is complicated and unclear in many aspects. Bladder wall thickness had been reported to be strongly associated with OAB, but its use as a screening tool remains controversial. Besides, few studies reported patterns of sexual dysfunction in female patients with lower urinary tract symptoms (LUTS). Therefore the aims of our study were to analyze the bladder wall blood perfusion pattern in female LUTS patients, the association of between the bladder wall blood perfusion pattern and the efficacy of anti-muscarinic treatment for female OAB, and the patterns of sexual dysfunction in the female LUTS patients.

Condition Intervention
Lower Urinary Tract Symptoms
Drug: Tolterodine SR

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Far Eastern Memorial Hospital:

Primary Outcome Measures:
  • Blood flow pattern after antimuscarinics [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Blood flow patterns between different LUTS subgroups [ Time Frame: 1 day ]

Estimated Enrollment: 300
Study Start Date: July 2010
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Bladder wall blood perfusion pattern Drug: Tolterodine SR
Tolterodine SR 4 mg qd


Ages Eligible for Study:   20 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • all cases are female patients with lower urinary tract symptoms

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01282840

Far Eastern Memorial Hospital Recruiting
Pan-Chiao, Taiwan
Contact: Hsiao Sheng Mou, MD    +886-2-89667000 ext 124   
Sponsors and Collaborators
Far Eastern Memorial Hospital
National Science Council, Taiwan
  More Information

Responsible Party: Sheng-Mou Hsiao, Chief, Department of Obstetrics & Gynecology, Far Eastern Memorial Hospital Identifier: NCT01282840     History of Changes
Other Study ID Numbers: 099049-F
Study First Received: January 23, 2011
Last Updated: September 4, 2016

Keywords provided by Far Eastern Memorial Hospital:

Additional relevant MeSH terms:
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Tolterodine Tartrate
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents processed this record on May 23, 2017